Kliemann, Nathalie
Viallon, Vivian
Murphy, Neil
Beeken, Rebecca J.
Rothwell, Joseph A.
Rinaldi, Sabina
Assi, Nada
van Roekel, Eline H.
Schmidt, Julie A.
Borch, Kristin Benjaminsen
Agnoli, Claudia
Rosendahl, Ann H.
Sartor, Hanna
Huerta, José María
Tjønneland, Anne
Halkjær, Jytte
Bueno-de-Mesquita, Bas
Gicquiau, Audrey
Achaintre, David
Aleksandrova, Krasimira
Schulze, Matthias B.
Heath, Alicia K.
Tsilidis, Konstantinos K.
Masala, Giovanna
Panico, Salvatore
Kaaks, Rudolf
Fortner, Renée T.
Van Guelpen, Bethany
Dossus, Laure
Scalbert, Augustin
Keun, Hector C.
Travis, Ruth C.
Jenab, Mazda
Johansson, Mattias
Ferrari, Pietro
Gunter, Marc J.
Funding for this research was provided by:
European Commission
Centre International de Recherche sur le Cancer
Danish Cancer Society
Ligue Contre le Cancer
Institut Gustave-Roussy
Mutuelle Générale de l'Education Nationale
Institut National de la Santé et de la Recherche Médicale
German Cancer Aid
German Cancer Research Center
Federal Ministry of Education and Research
Deutsche Krebshilfe
Deutsches Krebsforschungszentrum
Federal Ministry of Education and Research
Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy
National Research Council
Dutch Ministry of Public Health
Welfare and Sports
Netherlands Cancer Registry
LK Research Funds
Dutch Prevention Funds
Dutch ZON
World Cancer Research Fund (ERC-2009-AdG 232997)
Nordforsk, Nordic Centre of Excellence programme on Food, Nutrition and Health
Health Research Fund (PI13/00061 to Granada; PI13/01162 to EPIC-Murcia)
Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra
Catalan Institute of Oncology
Swedish Cancer Society
Swedish Research Council
County Councils of Skåne and Västerbotten
Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491; C8221/A19170 to EPIC-Oxford and C1418/A14133 to Intercept)
Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford)
Yorkshire Cancer Research Academic Fellowship funding
Article History
Received: 9 December 2020
Accepted: 22 March 2021
First Online: 30 April 2021
Declarations
:
: All EPIC study participants provided written informed consent and the study was approved by the ethics committee at the International Agency for Research on Cancer (IARC) and the local ethics centres. The Intercept study was approved by the London–Harrow Research Ethics Committee (reference: 13/LO/0080) and all study participants provided written informed consent.
: Not applicable.
: The authors declare that they have no competing interest.